NCT06073418

Brief Summary

The advances in early detection coupled with improvements in treatments have led to an ever increasing number of breast cancer survivors. New methods to improve outcomes, including strategies aimed at improving the quality of life and reducing the risk of other diseases, may complement the currently available treatment options. In particular, interventions targeting diet, weight and physical activity can reduce the risk of cancer occurrence, prevent cancer recurrence, and improve survival and the quality of life.This cross-sectional, prospective, observational study aims at evaluating dietary habits and nutritional knowledge in patients with early hormone receptor positive and hormone receptor negative breast cancer.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,098

participants targeted

Target at P75+ for all trials

Timeline
72mo left

Started Oct 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress39%
Oct 2022Jul 2032

Study Start

First participant enrolled

October 28, 2022

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

September 1, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 10, 2023

Completed
8.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2032

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2032

Last Updated

October 10, 2023

Status Verified

October 1, 2023

Enrollment Period

9.7 years

First QC Date

September 1, 2023

Last Update Submit

October 5, 2023

Conditions

Outcome Measures

Primary Outcomes (3)

  • Evaluation of nutritional knowledge in patients with surgically removed early breast cancer

    Median and interquartile range of items of nutritional knowledge questionnaire in patients with surgically removed early breast cancer

    At baseline and at 3-5 years of follow up

  • Evaluation of dietary habits in patients with surgically removed early breast cancer

    Frequency of different answers at dietary habits questionnaire

    At baseline and at 3-5 years of follow up

  • Evaluation of physical activity in patients with surgically removed early breast cancer

    Frequency of different answers at activity questionnaire

    At baseline and at 3-5 years of follow up

Secondary Outcomes (9)

  • Association between nutritional knowledge and physical activity

    At baseline and at 3-5 years of follow up

  • Association between nutritional knowledge and dietary habits

    At baseline and at 3-5 years of follow up

  • Association between dietary habits and physical activity

    At baseline and at 3-5 years of follow up

  • Association between dietary habits and BMI

    At baseline and at 3-5 years of follow up

  • Association between dietary habits and waist to hip ratio

    At baseline and at 3-5 years of follow up

  • +4 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients with early stage hormone receptor positive breast cancer treated at the Department of Medical Oncology and Cancer Prevention, IRCCS National Cancer Institute of Aviano and at the other involved clinical centers considered eligible for the study will be enrolled, after providing written informed consent.

You may qualify if:

  • Patients with surgically removed early stage (I-IIIa) hormone receptor-positive or hormone receptor negative breast cancer. Patients with hormone receptor-positive breast cancer can be in treatment with endocrine therapy; patients with hormone receptor-negative tumors have to be in follow-up. Concomitant use of targeted therapies with anti-hormonal agents is allowed only in adjuvant setting
  • Female patients ≥18 years of age.
  • Written informed consent must be obtained before any study-related assessment is performed

You may not qualify if:

  • Patients with advanced/metastatic breast cancer.
  • Patients with early breast cancer receiving (neo)adjuvant chemotherapy or anti-HER2 agents
  • Patients receiving active treatment for secondary primary tumors (excluding basal cell carcinoma or in situ neoplasias)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS, Centro di Riferimento Oncologico (CRO) di Aviano

Aviano, Pordonone, 33081, Italy

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Mattia Garutti, MD

    IRCCS-Centro di Riferimento Oncologico (CRO), Aviano (PN)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mattia Garutti, MD

CONTACT

Giulia Cudia, MSc

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 1, 2023

First Posted

October 10, 2023

Study Start

October 28, 2022

Primary Completion (Estimated)

July 1, 2032

Study Completion (Estimated)

July 1, 2032

Last Updated

October 10, 2023

Record last verified: 2023-10

Locations